Publications

Journal of clinical pharmacology

A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors.

01-08-2013

British journal of clinical pharmacology

Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

01-07-2013

Antimicrobial agents and chemotherapy

Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate.

01-06-2013

Drug delivery and translational research

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.

01-06-2013

Therapeutic drug monitoring

Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring.

01-04-2013

Biomedical chromatography : BMC

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

01-04-2013

British journal of clinical pharmacology

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

01-02-2013

Cancer chemotherapy and pharmacology

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

01-01-2013

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.

01-01-2013

Pharmaceutical research

Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab.

01-12-2012

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion.

01-12-2012

Bioanalysis

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.

01-11-2012

The AAPS journal

Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.

01-09-2012

Investigational new drugs

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).

01-08-2012

British journal of clinical pharmacology

Model-based treatment optimization of a novel VEGFR inhibitor.

01-08-2012

Journal of palliative care

Severe cannabinoid intoxication in a patient with non-small-cell lung cancer.

16-05-2012

Cancer

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.

01-05-2012

Journal of clinical pharmacology

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

01-03-2012

Journal of clinical pharmacology

Model-based evaluation of similarity in pharmacokinetics of two formulations of the blood-derived plasma product c1 esterase inhibitor.

01-02-2012

Drug metabolism and disposition: the biological fate of chemicals

Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.

01-02-2012

Cancer chemotherapy and pharmacology

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.

01-01-2012

International journal of pharmaceutics

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

28-11-2011

Lung cancer (Amsterdam, Netherlands)

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

01-11-2011

Journal of analytical toxicology

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

01-10-2011

Clinical pharmacology and therapeutics

Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.

01-07-2011

The AAPS journal

Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.

01-06-2011

Human antibodies

CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.

12-05-2011

Human antibodies

The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.

12-05-2011

Human antibodies

The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.

12-05-2011

Current clinical pharmacology

Pharmacodynamic biomarkers in model-based drug development in oncology.

01-02-2011

Computer methods and programs in biomedicine

Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

01-01-2011

Clinical pharmacokinetics

Clinical pharmacokinetics of therapeutic monoclonal antibodies.

01-08-2010

Journal of pharmacokinetics and pharmacodynamics

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.

01-08-2010

British journal of pharmacology

Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.

01-07-2010

Human antibodies

Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.

18-06-2010

British journal of clinical pharmacology

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.

01-05-2010

Investigational new drugs

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.

01-02-2010

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

01-11-2009

The oncologist

Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.

01-09-2009

Clinical cancer research : an official journal of the American Association for Cancer Research

Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.

15-06-2009

Cancer chemotherapy and pharmacology

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

01-06-2009

Investigational new drugs

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.

01-04-2009

Acta oncologica (Stockholm, Sweden)

Persistent neuropathy after treatment with cisplatin and oxaliplatin.

25-03-2009

Cancer chemotherapy and pharmacology

Carbamazepine induces bioactivation of cyclophosphamide and thiotepa.

01-02-2009

Journal of pharmacokinetics and pharmacodynamics

Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.

01-02-2009

Cancer biotherapy & radiopharmaceuticals

A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.

01-02-2009

Therapeutic drug monitoring

Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.

01-02-2009

Cancer treatment reviews

An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.

01-02-2009

Cancer chemotherapy and pharmacology

Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.

01-01-2009

British journal of clinical pharmacology

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

01-01-2009

A phase 1 comparative pharmacokinetic and cardiac safety study of two intravenous formulations of CO-101 in patients with advanced solid tumors.

Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet.

Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring.

Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.

Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.

Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab.

Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion.

Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue.

Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).

Model-based treatment optimization of a novel VEGFR inhibitor.

Severe cannabinoid intoxication in a patient with non-small-cell lung cancer.

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

Model-based evaluation of similarity in pharmacokinetics of two formulations of the blood-derived plasma product c1 esterase inhibitor.

Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.

Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.

Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).

Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.

Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.

Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicity.

Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies.

CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.

The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.

The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.

Pharmacodynamic biomarkers in model-based drug development in oncology.

Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.

Clinical pharmacokinetics of therapeutic monoclonal antibodies.

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.

Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.

Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.

A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.

Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.

Persistent neuropathy after treatment with cisplatin and oxaliplatin.

Carbamazepine induces bioactivation of cyclophosphamide and thiotepa.

Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.

A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.

Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.

An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.

Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.

Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

This site uses cookies